Active Implants said the device had already received the EU’s CE Mark Class IIb approval and was selling in select European markets, but the company is still applying for U.S. FDA approval while TriboFit goes through U.S. trials.
TriboFit, a polycarbonate-urethane acetabular implant, includes a gelatinous-like hydrophilic substance that imitates the fluid film layer naturally present in joints.
Read Active Implants’ release on European approval of TriboFit.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
